U.S. markets open in 8 hours 46 minutes

Psyence Group Inc. (PSYG.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.17000.0000 (0.00%)
At close: 10:55AM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1700
Open0.0000
Bid0.1600 x N/A
Ask0.1700 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume51,782
Market Cap14.54M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2640
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

      TORONTO, July 07, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce it has signed a partnership agreement with Clerkenwell Health (“Clerkenwell”). Clerkenwell is a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom. Psyence is developing market leading clinical trials in the field of palliativ

    • GlobeNewswire

      Psyence Group Announces Appointment of New Chief Executive Officer

      Current CEO to assume role of Executive ChairmanTORONTO, June 28, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has appointed Dr. Neil Maresky as Chief Executive Officer. Dr. Maresky joins Psyence after just having completed more than a decade at AstraZeneca Canada, most recently as Vice President of Scientific Aff

    • GlobeNewswire

      Psyence Group Announces Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development

      TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a public life science biotechnology company pioneering the use of natural psychedelics, is pleased to announce that through its wholly owned Jamaican subsidiary, Psyence Jamaica Limited (“Psyence Jamaica”), it has entered into a multi-year agreement (“Collaboration Agreement”) with the Jamaican government’s Scientific Research Council ("SRC"). The SRC is Jamaica’s principal public sector agency